Get notified when PRME files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrime Medicine appoints Svetlana Makhni as CFO with $495K salary and 800K stock options
Filed April 16, 2026 · Period ending April 7, 2026 · ~1 min read
Key Changes
-
high
Svetlana Makhni appointed CFO effective April 16, 2026, bringing 20+ years biotech finance experience including recent CFO role at Marengo Therapeutics. CEO Allan Reine steps down as principal financial officer but continues as CEO.
Item 5.02 verify on EDGAR → -
high
Board granted Makhni stock options for 800,000 shares (4-year vest: 25% at year one, monthly thereafter) plus 100,000 performance-based options. Exercise price set at grant date closing price on Nasdaq.
Item 5.02 verify on EDGAR → -
medium
Compensation package includes $495,000 base salary, $40,000 sign-on bonus, and 40% target annual bonus (approximately $198,000). Total first-year cash compensation around $733,000.
Item 5.02 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade PRME commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify